The estimated Net Worth of Bros. Advisors Lp667, L.P.B... is at least $82.6 Million dollars as of 13 March 2023. Bros B owns over 40,000 units of Kodiak Sciences Inc stock worth over $82,604,027 and over the last 3 years Bros sold KOD stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Bros B KOD stock SEC Form 4 insiders trading
Bros has made over 10 trades of the Kodiak Sciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Bros exercised 40,000 units of KOD stock worth $909,600 on 13 March 2023.
The largest trade Bros's ever made was buying 1,598,374 units of Kodiak Sciences Inc stock on 10 February 2022 worth over $106,947,204. On average, Bros trades about 246,783 units every 20 days since 2022. As of 13 March 2023 Bros still owns at least 33,442,926 units of Kodiak Sciences Inc stock.
You can see the complete history of Bros B stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Kodiak Sciences Inc
Over the last 6 years, insiders at Kodiak Sciences Inc have traded over $15,919,920 worth of Kodiak Sciences Inc stock and bought 10,439,459 units worth $472,964,631 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bros. Advisors Lp667, L.P.B..., and Victor Perlroth. On average, Kodiak Sciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $393,170. The most recent stock trade was executed by John A. Borgeson on 15 June 2024, trading 5,494 units of KOD stock currently worth $13,570.
What does Kodiak Sciences Inc do?
about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
What does Kodiak Sciences Inc's logo look like?
Complete history of Bros B stock trades at Incyte and Kodiak Sciences Inc
Kodiak Sciences Inc executives and stock owners
Kodiak Sciences Inc executives and other stock owners filed with the SEC include:
-
Victor Perlroth,
Chairman of the Board, President, Chief Executive Officer -
Jason Ehrlich,
Chief Medical Officer and Chief Development Officer -
John Borgeson,
Chief Financial Officer, Senior Vice President, Secretary -
Dr. Victor Perlroth M.D.,
Co-Founder, Chairman, CEO & Pres -
Dr. Jason S. Ehrlich M.D., Ph.D.,
Chief Medical Officer & Chief Devel. Officer -
John A. Borgeson CPA, M.B.A., MBA, CPA,
Sr. VP, CFO & Sec. -
Taiyin Yang,
Independent Director -
Robert Profusek,
Lead Independent Director -
Bassil Dahiyat,
Independent Director -
Richard Levy,
Independent Director -
Felix Baker,
Independent Director -
Charles Bancroft,
Independent Director -
Almas Qudrat M.Sc.,
Sr. VP of Quality Operations -
Dr. Hong Liang,
Sr. VP of Discovery Medicine -
Hong Liang,
See Remarks -
Bros. Advisors Lp667, L.P.B...,